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ABSTRACT
Purpose A mechanism-based PK-PD model was developed
to predict the time course of dopamine D2 receptor
occupancy (D2RO) in rat striatum following administration of
olanzapine, an atypical antipsychotic drug.
Methods A population approach was utilized to quantify both the
pharmacokinetics and pharmacodynamics of olanzapine in rats
using the exposure (plasma and brain concentration) and D2RO
profile obtained experimentally at various doses (0.01–40 mg/kg)
administered by different routes. A two-compartment pharma-
cokinetic model was used to describe the plasma pharmacoki-
netic profile. A hybrid physiology- and mechanism-based model
was developed to characterize the D2 receptor binding in the
striatum and was fitted sequentially to the data. The parameters
were estimated using nonlinear mixed-effects modeling .
Results Plasma, brain concentration profiles and time course
of D2RO were well described by the model; validity of the
proposed model is supported by good agreement between
estimated association and dissociation rate constants and in vitro
values from literature.
Conclusion This model includes both receptor binding
kinetics and pharmacokinetics as the basis for the prediction
of the D2RO in rats. Moreover, this modeling framework can
be applied to scale the in vitro and preclinical information to
clinical receptor occupancy.
KEY WORDS antipsychotic . dopamine D2 receptor
occupancy . koff . mechanism-based PK-PD . olanzapine .
translational model
ABBREVIATIONS
BBB blood–brain barrier
Bmax dopamine D2 receptor density
CB concentration of olanzapine bound to receptor
CEV concentration in extravascular brain compartment
CL systemic clearance
CLbev brain-extravascular clearance
CLbv brain-vascular clearance
D2RO dopamine-2 receptor occupancy
FIP bioavailability for intraperitoneal route of
administration
FOCE first order conditional estimation method
FSC bioavailability for subcutaneous route of
administration
fubrain unbound fraction in brain
fuplasma unbound fraction in plasma
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GOF goodness-of-fit plots
IAV inter-animal variability
koff receptor dissociation rate constant
kon receptor association rate constant
MW molecular weight
nM nanomoles/litre
OFV objective function value
PBPKPD physiology-based pharmacokinetic and
pharmacodynamic
PK-PD pharmacokinetic and pharmacodynamic
Q intercompartmental clearance
RSE relative standard error
SSE stochastic simulation and estimation
V1 volume of the central compartment
V2 volume of the peripheral compartment
Vbev volume of brain-extravascular compartment
Vbv volume of brain-vascular compartment
INTRODUCTION
Schizophrenia is a life-long and often devastating psychiatric
disorder which often begins in late adolescence or early
adulthood (1). Although the fundamental pathology of
schizophrenia remain ambiguous, it has been hypothesized
that an excessive level of striatal dopamine, which can be
caused by several factors, is responsible for development of
psychotic symptoms (2). This is also supported by the
elevation of dopamine release in naïve patients following
an acute amphetamine challenge (3). Preclinical and clinical
studies suggest that blockade of dopamine-2 receptors (D2
receptors) is the key pharmacological component to the
antipsychotic efficacy of both the typical and the newer
atypical antipsychotics (4,5). However, the degree of D2
receptor antagonism required for an antipsychotic efficacy is
still unclear. Some antipsychotics, for example clozapine,
show antipsychotic activity at a lower receptor blockade
(20―67%) than other antipsychotics (6). Aripiprazole, an
atypical antipsychotic, has been shown to be a partial agonist
on the D2 receptors (7). Kapur et al. (8) reported that the rate
of dissociation of antipsychotics from the D2 receptors drives
their efficacy and safety. These studies show that little is
known about the degree of target occupancy and the role of
the dynamic interactions between the drugs and the receptor
in schizophrenia treatment. Moreover, the importance and
influence of the distribution to the target site on the receptor
binding is not yet elucidated, and it is known that some
antipsychotics, e.g. risperidone and its active metabolite
paliperidone, are P-gp substrates and that therefore their
transport into brain involves a complex process of active and
passive transport (9). In addition, one of the other challenges
in schizophrenia drug discovery and development is scaling
and extrapolating the dopamine-2 receptor occupancy
(D2RO) obtained in preclinical studies to the clinical
situation in a quantitative manner.
Hence, there is a need for a tool in the drug discovery
process to characterize both penetration of the candidate
compound into the brain (target site distribution) and the
degree of D2RO, which could also support the scaling of
D2RO from rat to human. It is essential to have sufficient
information about the cascade of processes (distribution to
and in the brain, receptor occupancy as a net result of
association and dissociation) to generate such a tool. In
schizophrenia drug discovery research, the information
available to study the drug distribution into brain and the
time course of D2RO is rather sparse. Brain concentration
and D2RO are usually measured at the terminal time point,
unless a labor-intensive microdialysis technique is used.
Standard radioligand binding study protocols provide
limited data with respect to brain exposure and receptor
binding obtained at only one time point from one animal.
Pharmacokinetic and pharmacodynamic (PK-PD)
modeling tools are extensively used to characterize the
process between drug administration and its effect. In the
last two decades, population-based approaches have
become utilized to integrate the available sparse infor-
mation from different resources to study the underlying
PK-PD processes. These approaches provide population
mean parameter estimates and allow partition into inter-
individual and intra-individual variability. Mechanism-based
pharmacokinetic–pharmacodynamic models integrated with
population approaches were used to characterize and predict
the time course of pharmacodynamic responses in rats and
human (10,11). These models parameterize biophase
equilibration kinetics and receptor association-dissociation
kinetics to describe the drug binding to receptors. The
important feature of these mechanistic models is their
ability to distinguish the system- and drug-specific parameters,
which has been proven to be useful in the extrapolation
of treatment effects from rat to human. Moreover, these
PK-PD models, when combined with physiological
parameters, have the ability to predict human PK-PD
properties using prior information from in vitro and
preclinical studies (12).
In the present analysis, PK-PD tools were utilized to
describe the brain distribution and D2RO of olanzapine, an
atypical antipsychotic drug which is a dopamine D2 receptor
antagonist which has been proven to have antipsychotic
effects in the treatment of patients with schizophrenia (13).
Hence, a mechanism-based population PK-PD model
was developed to describe the time course of D2RO of
olanzapine, with emphasis on the modelling of receptor
association/dissociation kinetics. This model can be utilized
in the future to translate the in vitro and preclinical
information to D2RO in humans.
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METHODS
Data Management
This work was performed within the framework of the
Dutch Top Institute Pharma project: mechanism-based
population PK-PD modeling (http://www.tipharma.com).
This mechanism-based population PK-PD modeling
platform involves leading pharmaceutical companies world-
wide and academic institutes from The Netherlands. The
data used for this analysis were contributed by the
pharmaceutical companies who are the members of this
mechanism-based population PK-PD platform. The data
was anonimized, except the modeler was aware that the
data were sourced from three industrial partners: Janssen
Research and Development, Belgium, Merck Sharp and
Dohme Limited—The Netherlands, and Pfizer Global
Research and Development—USA. The dataset included
plasma and brain exposure data of olanzapine and its
D2RO measured at different time intervals from 12
different studies, which consisted of 283 rats of either the
Wistar or Sprague-Dawley strain. The experimental pro-
cedures for the plasma sample collection, brain dissection,
tissue homogenization, and D2RO measurements were
similar across the different study sites, and these procedures
were published elsewhere (4,14). Exposure and occupancy
information was obtained following the administration of
olanzapine by either intraperitoneal, subcutaneous or
intravenous route in a wide range of single doses (0.01 to
40 mg/kg body weight). More details about the studies and
data are depicted in Table I.
Modeling Tools
A population-based approach was employed to utilize all the
relevant information in order to obtain population parameter
estimates along with both the inter-animal and residual
variability. All the parameter estimations were performed with
the nonlinear mixed effects modeling software NONMEM
(version VI level 2.0) (15). Log-transformed plasma and brain
olanzapine concentrations were used for the data analysis,
and concentrations below the limit of quantification were
excluded from this analysis.
The inter-animal variability on the parameters was
modeled according to
Pi ¼ q » exp hið Þ
in which Pi is the estimate of parameter P for the ith animal, θ
the population estimate for parameter P, and exp(ηi) the
inter-animal random deviation of Pi from P. The values of ηi
are assumed to be normally distributed with mean zero and
variance w2i . Inter-animal variability is expressed as percent
coefficient of variation which is the square root of w2i »100.
The adequacy of the PK model was assessed on the basis of
goodness-of-fit plots, parameter correlations, and precision in
parameter estimates. An additional structural parameter or
inter-animal variability (IAV) was included in the model if the
resulting change in objective function value (OFV) was
>6.64 (p<0.01). Different types of residual error models
(proportional, additive, combined proportional, and additive)
were tested. Based on the visual inspection of the diagnostic
plots, a proportional error model was proposed to describe
residual error in the plasma and brain drug concentration, as
Table I Brief Description of the Studies That Were Used in This Analysis
Study
number
Dose in mg/kg
(min–max)
Number of
animals
Type of
observations
Route of
administration
Observation time
points (h)
Mode of D2RO
measurement
1 0.03 18 PC IP 0.25, 0.5,1,1.5,2,4 NA
2 0.3–30 15 PC, BC, RO IP 1 In vivo binding
3 0.01–10 28 PC IP 1 NA
4 0.01–30 32 PC IP 1 NA
5 3 20 PC, BC, RO IP 0.25, 0.5, 1,1.5,2 In vivo binding
6a 0.01–30 26 PC, BC, RO IP 1 In vivo binding
6b 0.01–30 22 PC, RO IP 1 In vivo binding
7 3 20 PC, BC, RO SC 0.5,1,2,4,6 In vivo binding
8 0.32 & 20 30 PC, BC, RO SC 0.5,1,2,4,8 Ex vivo binding
9 0.04–40 18 RO SC 1 In vivo binding
10 2.5 15 RO SC 0.25,0.5,2,4, 6 In vivo binding
11 0.01–40 33 RO SC 2 Ex vivo binding
12 2.5 3 PC IV 0.12,0.33,1,2,4,8, 24 NA
PC plasma concentration; BC total brain concentration; RO dopamine D2 receptor occupancy; IP intraperitoneal; SC subcutaneous; IV intravenous; NA not
applicable; min minimum dose used in the study; max maximum dose used in the study; In vivo binding and ex vivo binding studies were performed using
[3H]raclopride and [125 I]sulpiride as the radioligand, respectively
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ln(Yobsij) = ln(Ypredij) + εij in which Yobsij is the jth observed
concentration in the ith animal, Ypredij is the predicted
concentration. An additive term was used to account for the
unexplained variability in D2RO as Yobsij = Ypredij + εij, in
which Yobsij is the jth observed D2RO in the ith animal,
Ypredij is the predicted D2RO. The residual random variable
(εij) was assumed to be normally distributed with mean
zero and variance σ2. The residual error describes the
error terms which remain unexplained and refers to, for
example, dosing inaccuracies, assay and experimental
error (e.g., error in recording sampling times) and structural
model misspecifications.
During the analysis, Census (16) integrated with Xpose
(R package) (17) was used for NONMEM run management
and also for making different types of diagnostic plots,
which were used in the model selection process.
Population Pharmacokinetic Analysis
To determine the basic structural pharmacokinetic model for
olanzapine, one- and two-compartment models were tested.
Population pharmacokinetic values of olanzapine were esti-
mated using the first-order conditional estimation method
(FOCE). This model was implemented by user-defined
differential equations using the ADVAN 9 subroutine in
NONMEM. Using this routine, the parameter’s systemic
clearance (CL in l/h/kg), volume of the central compartment
(V1 in l/kg), volume of the peripheral compartment (V2 in
l/kg), intercompartmental clearance (Q in l/h/kg), and
bioavailability for intraperitoneal (FIP) and subcutaneous
(FSC) routes of administration were estimated.
Hybrid Physiology-Based PK-PD Model
A mechanism- and physiology-based PK-PD model was
developed and evaluated for its usefulness in describing the
time course of brain concentration and D2RO. A four-
compartment hybrid physiology-based pharmacokinetic and
pharmacodynamic (PBPKPD) model was sequentially linked
to the plasma population pharmacokinetic model to describe
the concentration-time profile of olanzapine in brain and the
binding to D2-receptors in striatum, which consists of brain-
vascular, brain-extravascular, striatum-free, and striatum-
bound compartments (Fig. 1). Following administration,
olanzapine is transported from the plasma compartment to
the brain-vascular compartment; this process is assumed to be
influenced only by the cerebral blood flow. Only the unbound
olanzapine in this intravascular compartment crosses the
blood–brain barrier (BBB) and is transported into the brain-
extravascular compartment, which is governed by the brain-
extravascular clearance (CLbev). Furthermore, olanzapine is
transported from the brain-extravascular compartment to the
striatum compartment, where it can reversibly bind to the
dopamine receptor complex (Fig. 1). The receptor association
and dissociation processes were described using kon as the
receptor association rate constant (nM−1h−1), koff as the
receptor dissociation rate constant (h−1), and the Dopamine
D2 receptor density (Bmax) in rat striatum. The volumes of
brain-vascular (Vbv) and brain-extravascular (Vbev) compart-
ments were assumed to be equal to the physiological values in
the rat: 0.00024 l/kg and 0.00656 l/kg, respectively (18). The
clearance from the brain-vascular compartment (CLbv) was
assumed to be equal to the cerebral blood flow in rats, which
is 0.312 l/h/kg (18). The brain-extravascular and striatum-
free compartments were assumed to be equilibrated rapidly.
This was achieved by fixing the clearance between brain-
extravascular and striatum-free compartments (CLst) to a high
value. The unbound fraction of olanzapine in plasma (fuplasma)
and brain (fubrain) was fixed to the values obtained from
literature: 0.23 and 0.034, respectively (19). The brain-
extravascular clearance (CLbev), the binding parameters (kd
and koff), and the Bmax were estimated by fitting the PBPKPD
model to the experimentally obtained brain concentrations
and dopamine receptor occupancy data. Kd (an equilibrium
constant) and koff were estimated from the model, and kon
was derived as kon = koff/Kd. During this analysis, the
plasma pharmacokinetic parameters were fixed to the
parameter estimates obtained from the population pharma-
cokinetic analysis. This model was implemented through user-
defined differential equations in the ADVAN 9 subroutine in
Fig. 1 A schematic representation of the PBPKPD model. The model
incorporates different processes to explain the time course of D2RO. The
plasma pharmacokinetics describe the disposition of the drug in the
plasma, the brain pharmacokinetics describe the processes involved in the
transport of drug from plasma to brain, and the striatum compartment
explains the drug binding to receptors through the binding constants.
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NONMEM, and differential equations related to this pro-
cesses are provided in Appendix 1.
This model was based on the following assumptions: (1)
Cerebrospinal fluid flow does not significantly influence the
brain disposition, and (2) plasma pharmacokinetics are not
affected by brain disposition. The latter assumption allows
the plasma concentration-time profile to be described by a
conventional two-compartment model, independent of the
brain distribution. In addition, it allows a separate analysis
of the plasma concentration data to the population
pharmacokinetic model.
During model development, it was observed that the
model was not able to estimate Bmax, so this parameter was
assumed to be 48 nM, calculated as the maximum
concentration of olanzapine bound to this receptor (20).
Due to the scarcity of data, no inter-animal variability was
assumed in the PBPKPD model. In vivo and ex vivo binding
studies were performed to measure the D2RO in rats, so it
was also attempted to estimate separate binding constants for
each in vivo and ex vivo studies. Moreover, an active efflux
parameter was added in the model to check for the influence
of active drug transport across the BBB.
Sensitivity Analysis
The objective of this analysis was to develop a stable
mechanism- and physiology-based PK-PD model that could
be supported by the data used in the analysis and with a
minimum number of parameters to be estimated. Hence, it was
decided to perform a sensitivity analysis so that the model could
be reduced by removing parameters, which have little or no
influence on the model outputs. Hence, the pharmacodynamic
parameters Kd (derived as koff/kon), koff, kon, and Bmax were
perturbed to determine their influence on the D2RO. A series
of simulations were conducted with differing parameter
values, which were varied 5- and 10-fold on the lower and
higher side of the base value (model parameter estimate).
Each simulation was conducted by altering one parameter at
a time and fixing all remaining parameter values. The outputs
considered for the parameter sensitivity analysis were the
simulated D2RO-time profiles with respect to the altered
pharmacodynamic parameter. All simulations were per-
formed using R (version 2.10). Primarily, 3 mg/kg dose was
selected for this analysis, as this is the intermediate dose in the
available dataset. Subsequently, lower and higher dose levels
to 3 mg/kg dose were also included in this analysis. D2RO
profiles were generated over a 24-hour time interval.
Model Evaluation
The bootstrap resampling technique and stochastic simulation
and estimation (SSE) were used as model evaluation tools to
check the stability and adequacy of the model, respectively. In
the bootstrap resampling technique, bootstrap replicates were
generated by sampling randomly from the original data set with
replacement. One thousand replicate data sets were obtained
using the bootstrap option in the software package Perl Speaks
NONMEM (PsN, version 3.2.4) (21). This resampling was
stratified based on the three dose levels (low, medium, and
high). Low, medium, and high dose levels included the doses
ranges from 0.01 to 0.63 mg/kg, 1 to 3 mg/kg, and 10 to
40 mg/kg, respectively. Parameter estimates for each of the
re-sampled data sets were obtained by fitting the final model
using NONMEM. Finally, median and 90% confidence
intervals of all model parameters were calculated, and the
medians of the bootstrap estimates were compared with
parameter values obtained from the original dataset. Further-
more, a simulation-based evaluation was performed using the
SSE option as implemented in PsN. Briefly, the final
PBPKPD model was used to both stimulate 1,000 datasets
and subsequently estimate PK-PD parameters from these
simulated datasets. The accuracy in parameter estimation was
assessed from the bias as calculated below.
For instance, bias is calculated for koff as
Bias %ð Þ ¼ Median kof f ið1::nÞ
  True koff =True koff»100%
where koffi is the population mean koff for the ith simulated
dataset, n is the number of simulations, True koff is the
value which was used for the simulation.
Predictive Check for D2RO
A predictive check was performed to determine whether the
final PBPKPD model provides an adequate description of
D2RO. One thousand datasets were simulated from the
final PBPKPD parameter estimates to compare the
distribution of simulated D2RO with the observed D2RO.
The median, lower (5%), and upper (95%) quantiles of the
simulated D2RO were calculated for a time period between
0 and 360 min after olanzapine administration.
Application of the Rat PBPKPD Model
Rat PBPKPD model structure was integrated with available
population pharmacokinetic parameters from human plasma
concentration-time data, in vitro binding constants, fraction
unbound in human plasma (22), and human brain physiolog-
ical information (23) to predict the human D2RO of
olanzapine. All the parameters which were used for the
simulations are tabulated in Table II. Distribution of
olanzapine across the BBB surrogated with permeability
surface area product (PS) was calculated as a product of
in vitro apparent membrane permeability (Papp, which is
15.7 *10−6 cm/s) (19) value and human brain endothelial
surface area (20 m2) (24). One thousand human D2RO-time
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curves were simulated for 10 mg/day and 20 mg/day dose
levels, administered orally. Inter-individual variability (IIV) in
the plasma population pharmacokinetic parameters was
accounted in these simulations. The observed human D2RO
was taken from the published literature domain (25,26). These
observed values were measured at steady-state conditions after
varying treatment duration across different studies. Hence, the
simulations were made at steady-state conditions, which were
achieved within 2 weeks of drug treatment. Berkeley
Madonna (version 8.3.18, Berkeley Madonna Inc, University
of California, USA) was used in this simulation study.
The predictive power of this translational approach was
determined by comparing the simulations with observed
human D2RO.
RESULTS
Population Plasma Pharmacokinetics
A two-compartment model best described the plasma
pharmacokinetics of olanzapine. The appropriateness of the
two-compartment over the one-compartment model was
based on the visual comparison of goodness-of-fit (GOF) plots
and the lower objective function. Population pharmacokinetic
parameter estimates are given in Table III. The observed and
population-predicted concentration of olanzapine is depicted
in Fig. 2. All structural pharmacokinetic parameters were
estimated precisely with acceptable relative standard error
(RSE) which varied between 9% and 30%. The absorption
Table II Population Pharmacokinetic Parameters, Passive Membrane Permeability, Physiological Parameters and In Vitro Binding Values Used for the
Simulations
Parameter Values used in human D2RO Simulations Source
CL/F (l/h) 19.5 (58)a (25)
V/F (l) 1,150 (75)a (25)
Ka (h−1) 0.600 (32)a (25)
koff (h−1) 2.34 (37)
Kd (nM) 5.10b (38)
fraction unbound in plasma 0.0700 (22)
fraction unbound in brain 0.034 (19)
Human cerebral blood flow (l/h) 36.0 (24)
Human brain extravascular volume (l) 1.4 (23)
Human brain vascular volume (l) 0.150 (23)
CLbev (l/h) 11.3 –
c
CL/F clearance; Ka absorption rate constant; V/F central volume of distribution
a Population mean (inter-individual variability as %CV)
b In vitro Ki value assumed as Kd
cCalculated as Papp* human brain endothelial surface area
Table III Population Pharmacokinetic Parameter Estimates from the Original Data Set and Resulting from 1,000 Bootstrap Replicates for V1, CL, V2, Q
with 90% Confidence Interval (CI)
Parameter Original dataset (%RSE) Median of 1,000 bootstrap replicates 90% CI from Non-parametric bootstrap
V1(l/kg) 4.22 (9) 4.17 3.61–4.93
CL (l/h/kg) 3.21 (9) 3.12 2.74–3.65
V2 (l/kg) 2.23 (14) 2.23 1.87–2.87
Q (l/h/kg) 1.70 (30) 1.67 1.19–2.92
FIP 0.636 (12) 0.633 0.538–0.771
Inter-animal variability
IAV-CL (%CV) 56 (19) 55 47–66
IAV-F1 (%CV) 87 (18) 87 73–98
Residual variability
Proportional error 0.141 (7) 0.130 0.073–0.159
%RSE = Relative standard error as obtained from the COVARIANCE option of NONMEM
IAV = Inter-animal variability calculated as 100×√ω2 , where ω2 is the variance term
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Fig. 2 Goodness-of-fit plots for the final PBPKPD model. Depicted are scatter plots of the observed olanzapine concentrations or D2RO vs. population
predictions and scatter plots of the population conditional weighted residuals vs. time.
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rate constant was not estimable due to lack of informa-
tion on early time points for both the intraperitoneal and
the subcutaneous routes of administration, and hence it
was assumed that olanzapine was administered directly
into the central compartment. A relative bioavailability
was estimated for the intraperitoneal route of adminis-
tration. The bioavailability for the subcutaneous route of
administration was estimated to be close to 1. Indeed,
fixing this parameter improved the model convergence
with a successful covariance step, so the bioavailability
for the subcutaneous route of administration was as-
sumed to be complete for further modeling. Estimation
of inter-animal variability was possible only for CL and
FIP and was estimated as 56% and 87%, respectively. No
trend or pattern was observed in the conditional weighted
residual diagnostics versus time and in the population
predictions versus time, which demonstrates that this model
adequately describes the time course of olanzapine plasma
concentration (Figs. 2 and 3).
Hybrid Physiology-Based PK-PD Model
Initially, a PBPKPD model was developed, which included
the effect of binding to the receptor on the free drug
concentrations at the receptor binding sites (Fig. 1). Parameter
estimates that were obtained using this model are tabulated
(Table IV). Later, a sensitivity analysis was performed to
identify whether the model could be reduced by removing
any parameters that were not influencing the model output
(s). The simulated D2RO profiles (model outcome) following
variations in Kd, kon, koff, and Bmax for a dose of 3 mg/kg
are shown in Fig. 4. This sensitivity analysis clearly showed
that Bmax did not influence the model output when
perturbed to different values, whereas perturbations of the
values Kd, kon, and koff all affected the D2RO to some extent.
This sensitivity analysis was also performed using lower and
higher dose levels, which resulted in similar observations to
those at the 3 mg/kg dose level. As little or no influence of the
parameter Bmax was shown at any of the doses, a reduced
model with an alternative assumption was proposed as
described in Fig. 5. Briefly, this model assumes that binding
to dopamine receptors does not affect the brain concentration
significantly and thereby allows for dropping the striatum-free
compartment from the full model. In other words, it is
assumed that a relatively low fraction of the drug in the brain
extra-vascular compartment binds to the dopamine receptor.
Further, this reduced model was subjected to model evalua-
tion. The parameter estimates obtained from this model were
close to the earlier model with Bmax (Table IV), indicating that
the reduced model is equivalent to the full model. There were
no significant parameter correlations (R>0.95) reported in the
NONMEM output between any of the PK-PD model
parameters, indicating the uniqueness of the parameter
estimates obtained from the reduced model. Information
about the brain concentration levels was limited to one
observation per animal, which leaves no opportunity to
estimate both inter- and intra-individual variability for brain
clearance. No trend or pattern was observed in the
Fig. 3 Observed and predicted
olanzapine concentrations and
D2RO vs. time. Open circles
represent the observed
olanzapine concentrations or
D2RO; the solid line represent the
population predictions for 3 mg/kg
dose of olanzapine administered
subcutaneously.
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conditional weighted residual diagnostics versus time and in the
population predictions versus time, which demonstrates that
this model adequately describes the time course of olanzapine
brain concentration and D2RO (Figs. 2 and 3). Different
sources of the data and data scarcity explain the high residual
variability of the brain concentrations.
Model Evaluation
Population Plasma Pharmacokinetic Model
In the bootstrap analysis of the population plasma
pharmacokinetic model, all the replicates were minimized
Table IV Population Brain Pharmacokinetic and Pharmacodynamic Parameter Estimates from Full and Reduced PBPKPD Model
Parameter Full model (FM) Reduced model (RM) % difference
Population mean (%RSE) Population mean (%RSE)
CLbev(l/h/kg) 0.433 (16) 0.394 (15) −10
Kd (nM) 14.6 (7) 14.7 (8) <1
koff (h−1) 3.04 (24) 2.62 (24) −16
kon (nM−1 h−1)a 0.208 0.178 −17
Proportional error (BC) 0.479 (6) 0.479 (6) <1
Additive error (D2RO) 0.136 (5) 0.136 (5) <1
%RSE = Relative standard error as obtained from the COVARIANCE option in NONMEM
% difference calculated as 100-(Parameter estimate-RM*100/Parameter estimate-FM)
BC brain concentration; D2RO dopamine D2 receptor occupancy
a kon derived as koff/Kd
Fig. 4 Simulated drug
concentration-time profiles for
perturbations in different pharma-
codynamic parameters at the
3 mg/kg dose level. The values
were perturbed 5- and 10-fold at
the higher and lower end of the
base value. The fold variations are
denoted by numerals
corresponding to the extent of
variation. The perturbations at the
lower end of the base parameter
values are denoted by the letter L
and at the higher end by the letter
G. For example, L10 indicates a
value 10-fold lower than the
base value of the parameter. This
nomenclature is adapted from
reference 27.
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successfully. The population estimates as well as the
residual error of this model are in close agreement with
the median values as depicted in Table III. Difference in
the estimated parameters from the final model between
the original observed plasma data and the combined
bootstrap replicates was <3% for all the parameter
estimates.
Hybrid Physiology-Based PK-PD Model
In the bootstrap analysis, 960 out of 1,000 bootstrap
replicates minimized successfully. The population estimates
as well as the residual error terms of the final model are in
close agreement with the median values of the 960
successful bootstrap replicates. The median bootstrap
estimates and 90% non-parametric bootstrap confidence
intervals are depicted in Table V. In Fig. 6, the distribution
of the PK-PD parameter estimates from the 1,000
simulated datasets is displayed as a histogram. Nine
hundred fifty-five out of 1,000 simulated datasets mini-
mized successfully. The bias for CLbev, Kd, koff was 2.2,
0.7, and 0.5%, respectively. The bias for the residual
variability on brain concentration and D2RO was −0.2 and
−0.7%, respectively.
Predictive Check for D2RO
The result of the predictive check for D2RO is depicted in
Fig. 7. More than 80% of the observed olanzapine D2RO
are within the range of the simulated upper (95%) and
lower (5%) quantiles of the simulated D2RO.
Application of the Rat PBPKPD Model
This hybrid PBPKPD model structure, using available
human pharmacokinetic model parameters, in vitro
Fig. 5 The reduced model incorporates different processes to explain
the time course of D2RO. This model excluded the non-influential
parameter Bmax from the full model. This reduced model is based on the
assumption that binding to dopamine receptors does not affect the free
drug concentration in the brain.
Table V Population Brain Pharmacokinetic and Pharmacodynamic Parameter Estimates from the Original Data Set and Resulting Median 1,000 Bootstrap
Replicates with 90% Confidence Interval for the Reduced Model
Parameter Original dataset (%RSE) 940 bootstrap replicates (n=940) 95%CI from non-parametric bootstrap
CLbev(l/h/kg) 0.394 (15) 0.398 0.276–0.648
Kd (nM) 14.7 (8) 14.6 12.2–17.7
koff (h−1) 2.62 (24) 2.64 1.58–6.36
Proportional error (BC) 0.479 (6) 0.470 0.380–0.560
Additive Error (D2RO) 0.136 (5) 0.141 0.121–0.152
%RSE = Relative standard error as obtained from the COVARIANCE option in NONMEM
BC brain concentration; D2RO dopamine D2 receptor occupancy
Fig. 6 Histograms of CLbev, Kd, and koff (in logarithmic scale) based on
the 1,000 stochastic simulations and estimations. Median values are
plotted with blue solid lines and overlaid with the true parameter estimates
(red solid lines). The blue dotted lines represent the 25th and 975th values
of 1,000 parameter estimates.
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permeability, and binding data, predicted the human
D2RO for olanzapine at both 10 mg/day and 20 mg/day
dose levels well. The result of these simulations is depicted in
Fig. 8.
DISCUSSION
This work aimed at developing a mechanism- and
physiology-based PK-PD model for olanzapine, which
takes into account the barriers in drug transport to the
brain and describes the association and dissociation
kinetics of the drug to the D2-receptor. The mechanistic
nature and population basis of this model could provide a
reliable tool for translating D2RO between species that
may support future drug discovery efforts, both specifically
in the development of antipsychotics and more generally
in the development of drug targeting other receptors in the
brain.
A population approach is utilized here to integrate
sparse data from a range of experimental sources to
estimate the PK-PD parameters. Plasma pharmacokinetics
were fitted well using a two-compartment classical phar-
macokinetic model. There were only 3 rats with a full
plasma concentration-time profile after intravenous olanza-
pine administration, and during the modeling exercise, it
was observed that bioavailability of olanzapine adminis-
tered through the subcutaneous route was close to one with
low inter-animal variability. Hence, to stabilize and
increase the FIP parameter precision, it was assumed that
olanzapine administered by the subcutaneous route had a
bioavailability of 100%. However, high variability in FIP
was estimated, which may reflect dosing inaccuracies or a
variable first-pass effect. There are some deviations in the
observed and population-predicted olanzapine concentra-
tions, which could potentially be explained by covariates.
Nevertheless, a covariate analysis was not performed due
to lack of information on the individual characteristics of
the animals. Possible sources of this variability were
differences in the analytical methodologies which were
used to measure the plasma concentration. In addition,
the study sites where studies were performed (three
different pharmaceutical companies) could also be a
source of variation. However, no covariate relations were
graphically observed between different study sites and
pharmacokinetic parameters. Finally, population PK
model evaluation demonstrated the accuracy and preci-
sion of the developed population PK model. This
population pharmacokinetic model was utilized as a
driving force for the brain PBPKPD model.
Target-site distribution might be complex for drugs
acting on targets in organs protected by specific barriers
(e.g. the brain), so a detailed characterization of these
barriers is required to be included in the brain PBPKPD
for meaningful concentration and effect relationships. Drug
Fig. 7 Predictive check of the PBPKPD model for D2RO after olanzapine
administration, at 3 mg/kg dose. A number of 1,000 data sets were
simulated from the final PBPKPD parameter estimates. Depicted are the
observed D2RO (dots) and the shaded area represents the upper (95%)
and lower (5%) quantile of the simulated D2RO. Median of the simulated
D2RO are represented as solid line; median of the observed D2RO are
represented as dashed line.
Fig. 8 Observed and predicted steady-state D2 receptor occupancy in
humans after oral administration of 10 mg/day (a) or 20 mg/day (b) of
olanzapine. Simulations were performed using the rat PBPKPD model
structure integrated with in vitro apparent permeability and in vitro binding
information (Table II). Depicted are the observed D2RO (dots); shaded
area represents the 95% prediction limits of the simulated D2RO. The
medians of the simulated D2RO are represented as a solid line.
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distribution across the BBB was previously described by
several pharmacokinetic models, which utilized the drug
levels from extracellular fluid of brain to model the drug
transport across the BBB (28–30). These models explained
both the passive and active drug transport across the
BBB in a quantitative manner. The objective of this
study was to make a PK-PD model structure to explain
the drug transport of antipsychotics across the BBB and
the time course of D2RO which later can be utilized for
translating PK-PD information from rat to human. It is
expected that these PK-PD models, when combined with
physiological basis, have the ability to predict human
PK-PD properties using prior information from in vitro
and preclinical studies, so this PBPKPD model was
developed on a physiology basis, including brain-vascular
and brain-extravascular compartments to describe the brain
pharmacokinetics and striatum compartments to explain the
binding to dopamine D2 receptors. This physiology basis is
expected to enable this model structure to utilize the in vitro
permeability and any efflux-related information as a
surrogate to explain drug transport across the brain in
humans. Additionally, the observed brain drug concen-
trations were obtained from the whole brain homoge-
nates, which represent the drug in both vascular and
extravascular compartments of the brain. The brain-
vascular and brain-extravascular compartment structure
enable this PBPKPD model to adapt this type of brain
drug concentration data without any correction. This
PBPKPD model adequately described both the brain
concentration and D2RO. The brain pharmacokinetic
parameter CLbev describes the passive transport of
olanzapine across the blood-brain barrier. It has been
reported that olanzapine is a substrate for the BBB drug
transporter P-glycoprotein (P-gp) in mice (31). Therefore,
an active efflux parameter was added in the model to
account for the active transport of olanzapine across the
BBB. However, this additional parameter did not improve
the model fit, and, consequently, this additional parameter
was not retained in the final model. Moreover, there are
ambiguous reports about the active transport of olanza-
pine across the BBB in different species from both in vivo
and in vitro studies (32–34). A significant influence of lag-
time between drug exposure and D2RO is expected for
antipsychotic compounds and seen in the data. This model
identifies both brain distribution (transfer across BBB) and
binding kinetics (kon and koff) as determinants of this time
delay on effect. A simulation-based analysis also showed
that both these components are essential to explain this
time delay process (not shown).
The limited information on the brain concentrations
(one observation per animal) did not allow separating the
inter-animal and residual variability. Hence, no inter-animal
variability for brain pharmacokinetics were estimated, and this
resulted in a high residual variability (48%) for the brain
concentrations. In addition to the possible sources that were
discussed earlier, different surgical procedures, brain dissections
and extraction procedures could also cause high residual
variability.
The pharmacodynamic parameters were estimated by
incorporating a binding model to the brain pharmacoki-
netic model. This modeling exercise was started with the
assumption that the binding to the dopamine receptor did
affect the free drug concentration in the receptor vicinity,
which included the parameter for maximum binding
capacity (as Bmax) in the model. Later, sensitivity analysis
showed that the value of the parameter Bmax hardly
affected the model output. This observation could be either
due to the model structure or to the limited information
about this parameter. Hence, in the final model it was
assumed that binding to D2 receptors did not affect the free
drug concentration in the receptor vicinity. Nevertheless,
this model still holds its mechanistic nature by character-
izing the time course of D2RO on the basis of receptor
association and dissociation kinetics. It has been demon-
strated that antipsychotics differ in their koff (dissociation)
rate, which may determine the efficacy and safety of the
antipsychotics (35). Hence, the current population PK-PD
model for olanzapine is proposed, which allows the separate
characterization of the kinetics of target site distribution
and the receptor association and dissociation kinetics as
determinants of the time course of the dopamine D2RO.
This model, as implemented in NONMEM, was able to
estimate Kd and koff with acceptable RSE of 8 and 24%,
respectively. Kd and koff were estimated using the D2RO
data from both in vivo and ex vivo binding studies. However,
when it was attempted to estimate separate values of Kd
and koff for in vivo and ex vivo binding studies, this resulted in
imprecise koff estimates. Zasadny et al. (36) found a
significant correlation in the D2RO measured using ex vivo
binding and in vivo imaging techniques in rats. Hence, it is
agreeable to estimate single values of Kd and koff using the
D2RO from both ex vivo and in vivo studies. The validity of
the proposed model is supported by the good agreement
between the estimated pharmacodynamic parameters and
the in vitro koff (2.34 h −1) and Ki (17 nM) values in rats
(35,37).
The model evaluation tools indicated that some param-
eters (CLbev and koff) had wide bootstrap confidence
intervals. These wide bootstrap confidence intervals could
be due to scattered and unbalanced information available
from our dataset, which consists of D2RO information from
a wide range of doses (Table I), so the bootstrap procedure
could resample unrealistic datasets with very limited
information to estimate the PK-PD parameters, resulting
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in wide confidence intervals. However, the median boot-
strap parameter estimates are close to the model parameter
estimates, which indicates that this model could still be
accepted with confidence. Moreover, the results of the
predictive check for D2RO showed that most of the
observed D2RO at 3 mg/kg dose levels were within the
5th and 95th percentiles of the simulated values, so this
model described the observed D2RO reasonably well.
However, the median of the simulated values was not in
close agreement with the median of the observed data
(Fig. 6). This could be due to the limited and unbalanced
amount of D2RO observations available at each time
points.
This proposed PBPKPD model is intended to be utilized
in a translational framework to scale pharmacokinetic and
pharmacodynamic information from rats to human, so this
general translational framework was based on a
mechanism-based approach which accounts for the differ-
ent processes involved in the transport of drug to brain.
Moreover, this mechanism- and physiology-based PK-PD
model separates the drug-specific properties, which describe
the interaction between the drug and the biological system
(target affinity, occupancy), and system-specific properties,
which describe the functioning of the biological system.
Further, the utility of this proposed PBPKPD model was
tested for its ability to predict the human dopamine D2
receptor occupancy. These simulations were based on
in vitro koff values obtained from rat studies (35), in vitro
human D2 receptor binding values (38), and calculated
surrogate (for example, PS) for the drug transport across
BBB. Danhof et al. (39) proposed that the values of drug-
specific parameters such as target affinity are likely to be
identical between species and individuals. This would imply
that the binding rate constants estimated in rats can be used
in human as well to extrapolate the pharmacodynamics
from rat to human. However, several other studies showed
differences in receptor affinity and protein binding between
species (40). Notwithstanding divergent reports on the
species independence of drug-specific parameters, an
integration of allometric principles (41–43), in vitro infor-
mation, and a physiological basis to PK-PD modeling
would increase the prospective of translating effects from
rat to human. The human D2RO predictions at both dose
levels are acceptable as 24 out of 39 observed values are
within the 95% prediction limits. The predictions might
improve further by considering the inclusion of allometric
principles and in vitro in vivo correlations. Some antipsychotics,
e.g. risperidone and its active metabolite paliperidone, have
been extensively studied as P-gp substrates, and, therefore,
their transport into and from brain involves a complex
process of active and passive transport (9). This model
structure, with few modifications, will also allow for extend-
ing this approach for other drugs with active transport across
the BBB.
Hence, this proposed PBPKPD model, which accounts
for the barriers in drug transport and describes the
association and dissociation kinetics, may be a useful tool
to extrapolate the D2RO of antipsychotics from rat to
human.
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APPENDIX 1
Full Model:
d A1ð Þ=dt ¼ Q =V2ð Þ»A2  Q =V1ð Þ»A1  CL=V1ð Þ»A1
d A2ð Þ=dt ¼ Q =V1ð Þ»A1  Q =V2ð Þ»A2
d A3ð Þ=dt ¼ CLbv=V1ð Þ»A1  CLbv=V3ð Þ»A3  CLbev=V3ð Þ»f uplasma»A3 þ CLbev=V4ð Þ»f ubrain»A4
d A4ð Þ=dt ¼ CLbev=V3ð Þ»f uplasma»A3  CLbev=V4ð Þ»f ubrain»A4  CLst=V4ð Þ»f ubrain»A4 þ CLst=V5ð Þ»f ubrain»A5
d A5ð Þ=dt ¼ CLst=V4ð Þ»f ubrain»A4  CLst=V5ð Þ»f ubrain»A5  kon»f ubrain»A5» Bmax  CBð Þ þ koff»A6
d A6ð Þ=dt ¼ kon»f ubrain»A5» Bmax  CBð Þ  koff»A6
2502 Johnson et al.
where subscripts 1–6 represent volumes (V) and amount (A)
of olanzapine at central, peripheral, brain-vascular, brain-
extravascular, striatum-free and striatum-bound compart-
ments, respectively; CL, Q, CLbv, CLbev, CLst represent
clearance of olanzapine in the central, peripheral, brain-
vascular, brain-extravascular, striatum-free compartments,
respectively; CB is concentration bound to receptor as
(A6/V6)/(MW/1,000) in nM; MW is molecular weight of
olanzapine; and D2RO is calculated as CB/Bmax.
Note that the transport from the central compartment to
the brain-vascular compartment is not included in the
equation d(A1)/dt. This allows the plasma concentration-
time profile to be described by a conventional two-
compartment model, independent of the brain distribution.
Reduced Model:
Equations for d(A1)/dt, d(A2)/dt, and d(A3)/dt are identical
to the full model:
d A4ð Þ=dt ¼ CLbev=V3ð Þ»f uplasma»A3  CLbev=V4ð Þ»f ubrain»A4
d A5ð Þ=dt ¼ kon»f ubrain»CEV» 1 A5ð Þ  koff»A5
where subscripts 1–4 represent volumes (V) and amount (A)
of olanzapine at central, peripheral, brain-vascular, brain-
extravascular compartments, respectively; A5 is the frac-
tional D2 receptor occupancy; CL, Q, CLbv, CLbev
represent clearance of olanzapine in the central, peripheral,
brain-vascular, brain-extravascular compartments, respec-
tively; and CEV is the concentration in extravascular brain
compartment as (A4/V4)/(MW/1,000) in nM.
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